- Home
- VNT vs BLCO Comparison
VNT vs BLCO Comparison
Compare VNT & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNT
- BLCO
- Stock Information
- Founded
- VNT 2019
- BLCO 1853
- Country
- VNT United States
- BLCO Canada
- Employees
- VNT N/A
- BLCO N/A
- Industry
- VNT Industrial Machinery/Components
- BLCO Ophthalmic Goods
- Sector
- VNT Industrials
- BLCO Health Care
- Exchange
- VNT Nasdaq
- BLCO Nasdaq
- Market Cap
- VNT 5.4B
- BLCO 4.9B
- IPO Year
- VNT N/A
- BLCO 2022
- Fundamental
- Price
- VNT $43.71
- BLCO $14.93
- Analyst Decision
- VNT Strong Buy
- BLCO Hold
- Analyst Count
- VNT 8
- BLCO 11
- Target Price
- VNT $47.43
- BLCO $15.80
- AVG Volume (30 Days)
- VNT 1.2M
- BLCO 943.3K
- Earning Date
- VNT 07-31-2025
- BLCO 07-30-2025
- Dividend Yield
- VNT 0.24%
- BLCO N/A
- EPS Growth
- VNT 1.28
- BLCO N/A
- EPS
- VNT 2.63
- BLCO N/A
- Revenue
- VNT $3,041,400,000.00
- BLCO $4,891,000,000.00
- Revenue This Year
- VNT $2.32
- BLCO $7.10
- Revenue Next Year
- VNT $4.92
- BLCO $5.50
- P/E Ratio
- VNT $16.60
- BLCO N/A
- Revenue Growth
- VNT 1.16
- BLCO 8.81
- 52 Week Low
- VNT $27.22
- BLCO $10.45
- 52 Week High
- VNT $43.77
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- VNT 67.99
- BLCO 64.22
- Support Level
- VNT $41.98
- BLCO $14.24
- Resistance Level
- VNT $43.09
- BLCO $14.80
- Average True Range (ATR)
- VNT 0.90
- BLCO 0.44
- MACD
- VNT 0.05
- BLCO 0.05
- Stochastic Oscillator
- VNT 98.58
- BLCO 92.72
About VNT Vontier Corporation
Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3 billion in sales in 2024.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.